(3.210.184.142) 您好!臺灣時間:2021/05/09 09:35
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:王坤謄
研究生(外文):Kun-Teng Wang
論文名稱:CD94轉錄物與淋巴母細胞瘤間關係之研究
論文名稱(外文):CD94 Transcripts in Lymphoblastic Lymphoma
指導教授:許世明許世明引用關係
指導教授(外文):Shi-Ming Hsu
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:病理學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2004
畢業學年度:92
語文別:英文
論文頁數:50
中文關鍵詞:非霍奇金淋巴瘤自然殺手細胞淋巴母細胞瘤
外文關鍵詞:CD94/NKG2Lymphoblastic lymphoma
相關次數:
  • 被引用被引用:0
  • 點閱點閱:164
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
惡性淋巴瘤 (malignant lymphoma) 是原發於淋巴結和淋巴結外淋巴組織的惡性腫瘤,淋巴瘤係淋巴組織細胞發生異常變化增生而來。由於阻斷了正常細胞運作,在患者不知不覺下便形成所謂的淋巴瘤。一般而言,依發生病變細胞的不同,可將惡性淋巴瘤分成霍奇金病 (Hodgkin’s disease) 和非霍奇金淋巴瘤 (Non-Hodgkin’s lymphoma) 兩大類。
非霍奇金淋巴瘤是一種淋巴組織內淋巴細胞發生了不正常增生的一種新生異質瘤,而目前被發現有可能成為不正常增生的淋巴細胞包含了B 細胞,T 細胞以及自然殺手細胞 (Natural killer cell)。大部分淋巴瘤的分化來源大多是由 B 細胞和T 細胞所演變的,但極少數的淋巴瘤,例如自然殺手與T 細胞混合型 (NK/T-cell lymphomas),是由成熟的自然殺手細胞所分化增生而來的。淋巴母細胞淋巴瘤 (lymphoblastic lymphoma) 是由不成熟的T 細胞分化而來,而是否有可能由不成熟的自然殺手細胞分化,目前則未知。
而自然殺手細胞分別由刺激及抑制的接受器來調控,目前已知的接受器家族有三大類,分別是Ly49,CD94/NKG2,以及Killer cell Ig-like receptor (KIR)。而這三類的接受器都與主要組織相容複體第一型 (major histocompatibility complex class I)的辨識有關。
在本篇報告裡,我們發現LBL有不同CD94的轉錄物 (transcripts),並且這些LBL通常較偏好使用遠處啟動子 (distal promoter)。而這些不同的CD94轉錄物能在胸線中可見但在周邊血液 (peripheral blood)內的成熟自然殺手細胞中卻無發現,由此就能區別一部分的LBL是由未成熟的自然殺手細胞分化而來
Non-Hodgkin’s lymphoma is a heterogeneous group of neoplasms that arises from clonal proliferation of lymphoid cells, such as T-lymphocytes, B-lymphocytes, or NK-cells. Most lymphomas belong to the T- or B- lineage, but rare lymphomas, such as the NK/T-cell lymphomas of the nasal region, are lymphomas of mature NK-cells. Lymphomas derived from immature lymphoid cells have a specific designation, lymphoblastic lymphomas (LBLs). Most of them belong to the T-lineage. Lymphomas of immature NK-cells are possible, but not well defined.
NK cells are regulated by both activating and inhibitory receptors. Most important among them are three distinct receptor families, Ly49, CD94/NKG2, and Killer cell Ig-like receptor (KIR), which are involved in recognition of major histocompatibility complex (MHC) class I molecules by NK-cells. Recently, it was reported that CD94 transcription is under the controls of both a distal and a proximal promoter.
In this report, we showed that immature NK/T cells of the thymus use preferentially the distal promoter, whereas mature NK-cells of the peripheral blood use the proximal promoter. Significantly, a subset of LBLs also uses the distal promoter preferentially. This distinct pattern of CD94 transcripts can thus be used to define a LBL of the NK-lineage.
Abstract..................................................3
Chinese abstract..........................................4

Chapter 1 Introduction....................................5
1.1 Natural Killer cell.................................6
1.2 CD94 and NKG family.................................6
1.3 Non-Hodgkin’s lymphoma (NHL).......................7
1.3.1 Lymphoblastic lymphoma (LBL)...................7
1.4 Association between NK cells and LBL...............11
1.5 Dual promoters in human CD94 gene..................11
1.6 Searching for a distinct pattern of CD94
transcripts in LBLs................................11

Chapter 2 Preferential use of the distal promoter of CD94
(CD94 1A) characterizes an NK-Lymphoblastic Lymphoma.....12

Chapter 3 Construction of plasmids for CD94
transcriptional controls.................................35

Appendix.................................................43
1.Yokoyama WM. 1998. Natural killer cell receptors. Curr.
Opin. Immunol. 10 (3):298-305.
2.Biron CA, Brossay L. 2001. NK cells and NKT cells in
innate defense against viral infections. Curr Opin
Immunol. 13(4):458-64.
3.Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau
F, Gervois N. 2002. Expression of CD94/NKG2-A on human T
lymphocytes is induced by IL-12: implications for
adoptive immunotherapy. J. Immunol. 15; 168(10):4864-70.
4.Lopez-Botet M, Llano M, Navarro F, Bellon T. 2000. NK
cell recognition of non- classical HLA class I
molecules. Semin Immunol. 12(2):109-19.
5.Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM. 2003. CD94
transcripts imply a better prognosis in nasal-type
extranodal NK/T-cell lymphoma. Blood.1; 102 (7):2623-31.
6.Rodriguez A., M. Carretero, J. Glienke, T. Bellon, A.
Ramirez, H. Lehrach, F. Francis, and M. Lopez-Botet.
1998. Structure of the human CD94 C-type lectin gene.
Immunogenetics. 47:305
7.Yabe T., McSherry C., Bach F.H., Fisch P., Schall R.P.,
Sondel P.M., and Houchins J.P. 1993. A multigene family
on human chromosome 12 encodes natural killer-cell
lectins. Immunogenetics 37:455–60
8.Chang C., Rodriguez A., Carretero M., Lopez-Botet M.,
Phillips J.H., and Lanier L.L. 1995. Molecular
characterization of human CD94: a type II membrane
glycoprotein related to the C-type lectin superfamily.
Eur. J. Immunol. 25:2433–37
9.Wada H, Matsumoto N, Maenaka K, Suzuki K, Yamamoto K.
2004. The inhibitory NK cell receptor CD94/NKG2A and the
activating receptor CD94/NKG2C bind the top of HLA-E
through mostly shared but partly distinct sets of HLA-E
residues. Eur J Immunol. 34(1):81-90.
10.Bottino C, Vitale M, Pende D, Biassoni R, Moretta A.
1995. Receptors for HLA class I molecules in human NK
cells. Semin Immunol. 7(2):67-73.
11.Van Beneden K, Stevenaert F, De Creus A, Debacker V, De
Boever J, Plum J, Leclercq G.. 2001. Expression of
Ly49E and CD94/NKG2 on fetal and adult NK cells. J
Immunol. 1; 166(7):4302-11.
12.Hennessy BT, Hanrahan EO, Daly PA. 2004. Non-Hodgkin
lymphoma: an update. Lancet Oncol. 5(6):341-53.
13.Takei F, McQueen KL, Maeda M, Wilhelm BT, Lohwasser S,
Lian RH, Mager DL. 2001. Ly49 and CD94/NKG2:
developmentally regulated expression and evolution.
Immunol Rev. 181:90-103.
14.Hoelzer D, Gokbuget N. 2003. Treatment of lymphoblastic
lymphoma in adults. Best Pract Res Clin Haematol.15
(4):713-28.
15.Armitage JO, Weisenburger DD. 1998. New approach to
classifying non-Hodgkin''s lymphomas: clinical features
of the major histologic subtypes. Non-Hodgkin''s
Lymphoma Classification Project. J Clin Oncol. 16
(8):2780-95.
16.Perkins SL. 2000. Work-up and diagnosis of pediatric
non-Hodgkin''s lymphomas. Pediatr Dev Pathol. 3(4):374-
90.
17.Smithers DW. 1971. Summary of papers delivered at the
Conference on Staging in Hodgkin''s Disease (Ann Arbor).
Cancer Res. 31(11):1869-70.
18.Lieto LD, Borrego F, You CH, Coligan JE. 2003. Human
CD94 gene expression: dual promoters differing in
responsiveness to IL-2 or IL-15. J. Immunol. 15 1 7 1
(10):5277-86.
19.Ida H, Robertson MJ, Voss S, Ritz J, Anderson P. 1997.
CD94 ligation induces apoptosis in a subset of IL-2-
stimulated NK cells. J Immunol. 1; 159(5):2154-60.
20.Soslow RA, Baergen RN, Warnke RA. 1999. B-lineage
lymphoblastic lymphoma is a clinicopathologic entity
distinct from other histologically similar aggressive
lymphomas with blastic morphology. Cancer. 15; 85
(12):2648-54.
21.Wan TS, Ma SK, Chan GC, Ching LM, Ha SY, Chan LC. 2000.
Complex cytogenetic abnormalities in T-lymphoblastic
lymphoma: resolution by spectral karyotyping. Cancer
Genet Cytogenet. 1; 118(1):24-7.
22.Lin P, Jones D, Dorfman DM, Medeiros LJ. 2000.
Precursor B-cell lymphoblastic lymphoma: a
predominantly extranodal tumor with low propensity for
leukemic involvement. Am J Surg Pathol. 24(11):1480-90.
23.Carbone P.P., Kaplan H.S., Musshoff K., et al. 1971.
Report of the committee on Hodgkin’s disease staging
classification. Cancer Res. 11:1860-1
24.Tamura H, Ogata K, Mori S, An E, Tajika K, Sugisaki Y,
Dan K. 1998. Lymphoblastic lymphoma of natural killer
cell origin, presenting as pancreatic tumour.
Histopathology. 32(6):508-11.
25.Vivier E, Anfossi N. 2004. Inhibitory NK-cell receptors
on T cells: witness of the past, actors of the future.
Nat Rev Immunol. 4(3):190-8.
26.Mori KL, Egashira M, Oshimi K. 2001. Differentiation
stage of natural killer cell-lineage
lymphoproliferative disorders based on phenotypic
analysis. Br J Haematol. 115(1):225-8.
27.Wilhelm BT, Landry JR, Takei F, Mager DL. 2003.
Transcriptional control of murine CD94 gene:
differential usage of dual promoters by lymphoid cell
types. J. Immunol. 15; 171(8):4219-26.
28.Le Gouill S, Lepretre S, Briere J, Morel P, Bouabdallah
R, Raffoux E, Sebban C, Lepage E, Brice P. 2003. Adult
lymphoblastic lymphoma: a retrospective analysis of 92
patients under 61 years included in the LNH87/93
trials. Leukemia. 17(11):2220-4.
29.Moretta A, Bottino C, Vitale M, Pende D, Cantoni C,
Mingari MC, Biassoni R, Moretta L. 2001. Activating
receptors and coreceptors involved in human natural
killer cell-mediated cytolysis. Annu Rev Immunol.
19:197-223.
30.Carayannopoulos LN, Yokoyama WM. 2004. Recognition of
infected cells by natural killer cells. Curr Opin
Immunol. 16(1):26-33.
31.Brooks AG, Borrego F, Posch PE, Patamawenu A, Scorzelli
CJ, Ulbrecht M, Weiss EH, Coligan JE. 1999. Specific
recognition of HLA-E, but not classical, HLA class I
molecules by soluble CD94/NKG2A and NK cells. J.
Immunol.1; 162(1):305- 13.
32.Lin CW, Lee WH, Chang CL, Yang JY, Hsu SM. 2001.
Restricted killer cell immunoglobulin-like receptor
repertoire without T-cell receptor gamma rearrangement
supports a true natural killer-cell lineage in a subset
of sinonasal lymphomas. Am J Pathol. 159(5):1671-9.
33.Baird AM, Gerstein RM, Berg LJ. 1999. The role of
cytokine receptor signaling in lymphocyte development.
Curr Opin Immunol. 11(2):157-66.
34.Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. 1996.
IL-15: a pleiotropic cytokine with diverse
receptor/signaling pathways whose expression is
controlled at multiple levels. Immunity. 4(4):329-36.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
系統版面圖檔 系統版面圖檔